cleversearchs.com

https://www.fda.gov/search?s=dupixent&sort_bef_combine=rel_DESC

Search | FDA

The US Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).

https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/treatment

Eczema types: Atopic dermatitis diagnosis and treatment

Both abrocitinib and upadacitinib are FDA approved to treat moderate to severe atopic dermatitis when other treatments fail to work. Both of these JAK ...

U.S. Food and Drug Administration

https://www.fda.gov/news-events/press-announcements/fda-approves-new-eczema-drug-dupixent

FDA approves new eczema drug Dupixent | FDA

Mar 28, 2017 ... The US Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).

National Eczema Association

https://nationaleczema.org/blog/2022-treatment-roundup/

2022 Eczema Treatment Updates | National Eczema Association

Nov 30, 2022 ... At the close of last year, the FDA approved Adbry™ (tralokinumab-ldrm) for the treatment of moderate-to-severe AD in adults whose AD is not ...

PubMed

https://pubmed.ncbi.nlm.nih.gov/35587593/

Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe ...

Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis. Ann Pharmacother. 2023 Jan;57(1):86-98. doi: 10.1177/10600280221096713. Epub ...

Eli Lilly and Company

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and

FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and ...

Sep 13, 2024 ... FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis.

Arcutis Biotherapeutics

https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-15-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-6-years-of-age/

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the ...

Jul 9, 2024 ... FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age.

Wiley Online Library

https://onlinelibrary.wiley.com/doi/10.1111/all.16009

Treatment of atopic dermatitis: Recently approved drugs and ...

Jan 8, 2024 ... The κ-opioid-R-agonist difelikefalin, is approved for moderate-to-severe pruritus in adults requiring haemodialysis, and currently tested in ...

https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults

U.S. FDA Approves Pfizer's CIBINQO® (abrocitinib) for Adults with ...

Jan 14, 2022 ... ... treatment landscape for moderate-to-severe atopic dermatitis.” The most common adverse events reported in ≥5% of patients with CIBINQO ...

https://www.sanofi.com/en/media-room/press-releases/2020/2020-05-26-15-40-00-2038798

FDA approves Dupixent® (dupilumab) as first biologic medicine for ...

May 26, 2020 ... Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis.